Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Q1 2023 Earnings Call dated May. 11, 2023. Corporate Participants: Alicia Grande -- Vice President, Chief Financial Officer and Treasurer
Catalyst Pharmaceuticals Inc
-(CPRX)
XNAS:CPRX
Catalyst Pharmaceuticals Inc (CPRX) Q3 2022 Earnings Call Transcript
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Q3 2022 Earnings Call dated Nov. 10, 2022. Corporate Participants: Alicia Grande -- Vice President, Chief Financial Officer and Treasurer
CATALYST PHARMACEUTICALS INC (CPRX) Q2 2022 Earnings Call Transcript
CATALYST PHARMACEUTICALS INC (NASDAQ: CPRX) Q2 2022 earnings call dated Aug. 10, 2022 Corporate Participants: Alicia Grande -- Chief Financial Officer Patrick J. McEnany -- Co-Founder, Chairman,
CATALYST PHARMACEUTICALS INC (CPRX) Q1 2022 Earnings Call Transcript
CATALYST PHARMACEUTICALS INC (NASDAQ: CPRX) Q1 2022 earnings call dated May. 11, 2022 Corporate Participants: Alicia Grande -- Vice President, Chief Financial Officer &
Catalyst Pharmaceuticals Inc. (CPRX) Q4 2021 Earnings Call Transcript
Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) Q4 2021 earnings call dated Mar. 17, 2022 Corporate Participants: Alicia Grande -- Vice President, Chief Financial Officer and
Catalyst Pharmaceuticals Inc. (CPRX) Q4 2020 Earnings Call Transcript
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) Q4 2020 earnings call dated Mar. 16, 2021. Corporate Participants: Alicia Grande -- Vice President, Chief Financial
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) Q1 2020 Earnings Call Transcript
Catalyst Pharmaceuticals Inc (CPRX) Q1 2020 earnings call dated May 12, 2020 Corporate Participants: Alicia Grande -- Vice President, Chief Financial Officer and Treasurer
Catalyst Pharmaceutical (CPRX): Q4 2019 Earnings Snapshot
-- Catalyst Pharmaceutical (NASDAQ: CPRX) reported its fourth-quarter 2019 earnings of $0.07 per share versus $0.10 per share expected. -- Total revenue
Catalyst Pharmaceutical (CPRX): Q3 2019 Earnings Snapshot
-- Catalyst Pharmaceutical (NASDAQ: CPRX) reported third quarter 2019 earnings of $0.13 per share, vs. $0.11 per share expected. -- Net product
Catalyst Pharmaceuticals stock soars to record high
Catalyst Pharmaceuticals (NASDAQ: CPRX) stock soared to a record high of $7.67 on Wednesday as phase 3 trial results date is nearing
Catalyst Pharmaceuticals’ Q1 results beat estimates
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported first-quarter 2019 revenue and earnings that surpassed analysts’ expectations. Shares climbed around 4% in premarket hours on
Catalyst Pharmaceuticals stock soars to 12-year high
Catalyst Pharmaceuticals Inc. (CPRX) stock surged to a 12-year high of $5.59 on Wednesday. Investors were positive about the prospect of Firdapse
Catalyst Pharma loss widens in Q4 due to Firdapse launch
Catalyst Pharmaceuticals (Nasdaq: CPRX) reported a loss of $0.14 per share compared to $0.12 loss expected by the street. The increase in